RxDoctor Payments Data

Lisa Holmes

Family · Utica, NYNPI 1336451756

Payments from drug & device makers

$2,658in general payments, 2019–2025

Across 110 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Acadia Pharmaceuticals Inc$504
  • Otsuka America Pharmaceutical, Inc.$188
  • Avanir Pharmaceuticals, Inc.$174
  • SK Life Science, Inc.$146
  • AstraZeneca$135
  • plus $89 from 3 others

What the payments were for

  • Food & beverage$2,64299%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,658 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$188,207
Medicare patients
237
Services billed
2,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$85,546
TrulicityDulaglutide79$62,387
EliquisApixaban94$40,540
XareltoRivaroxaban56$29,445
OzempicSemaglutide29$29,260
RexultiBrexpiprazole40$28,988
EntrestoSacubitril/Valsartan49$22,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,800
XifaxanRifaximin11$16,829
MyrbetriqMirabegron41$15,404
Incruse ElliptaUmeclidinium Bromide39$15,288
JardianceEmpagliflozin27$14,929
JanuviaSitagliptin Phosphate25$12,450
Breo ElliptaFluticasone/Vilanterol28$11,958
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc94$9,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,422$85,54619 claims
Lilly USA, LLCTrulicity, Olanzapine$14$65,032158 claims
Otsuka America Pharmaceutical, Inc.Rexulti$188$28,98840 claims
AstraZenecaFarxiga, Symbicort$135$10,26830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →